RECRUITING

Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI Biomarker Panel and Algorithm to Detect Mucosal Healing in Moderate to Severe Ulcerative Colitis Patients.

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to determine the efficacy and outcome of the UCRI (an in-vitro diagnostics device in the form of a blood test and an algorithm) as a tool to detect mucosal healing (level of inflammation in the colon) in people with moderate-to-severe ulcerative colitis treated with anti-TNFα. Another reason is to explore additional biomarkers in blood, stool or voice to detect disease activity and/or mucosal healing. A tool to detect the level of inflammation in the colon based on blood, stool or voice biomarkers may reduce the need or the number of invasive endoscopic procedures. This is an observational study and no treatment decision nor clinical intervention will be done based on results during this study and all collected data will be used only for the goal of the study and for obtaining FDA IDE for a follow-up study.

Official Title

Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI In-vitro Diagnostics Device to Detect Treatment Response Measured by Endoscopic Healing in Moderate to Severe Ulcerative Colitis Patients Treated With Anti-TNF-a.

Quick Facts

Study Start:2021-08-24
Study Completion:2024-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04897282

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ulcerative colitis patients with Mayo Endoscopic Subscore of 2-3
  2. * Start/switch anti -TNFa treatment
  3. * Capable of at-home fCal testing
  1. * Pregnant women
  2. * anti -TNFa dose escalation/adjustment
  3. * Inability to undergo endoscopic assessments due to Proctitis
  4. * Diagnosed with infectious diseases
  5. * Steroid refractory

Contacts and Locations

Study Contact

Avinoam A Dukler, PhD
CONTACT
8057912094
ucri@glycominds.com

Study Locations (Sites)

UC Davis Inflammatory Bowel Disease Center
Sacramento, California, 95816
United States

Collaborators and Investigators

Sponsor: Glycominds, LLC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-08-24
Study Completion Date2024-12-31

Study Record Updates

Study Start Date2021-08-24
Study Completion Date2024-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Ulcerative Colitis